More millions for Wyeth chief Poussot

More reasons to wish you were Wyeth's CEO: Bernard Poussot got a 69 percent raise in his compensation package for 2008. Just on a percentage point basis, that increase would be 23 times what the lucky ones among the masses got last year: 3 percent.

When you look at it in dollar terms, though, the multiples get to be enormous. Poussot's compensation deal amounted to $21.3 million in 2008, up from $12.7 million in 2007. That's a difference of $8.6 million. According to Salary.com, the median compensation and benefits package for a pharma rep is about $104,500, so Wyeth's chief made about 204 times what the average rep makes. Nice work if you can get it. Plus, for "security and other reasons" Poussot is required to use the company jets and helicopters when he flies.

The rest of Wyeth's executives didn't do too badly, either. CFO Gregory Norden made $7.7 million, up from $3 million in 2007. SVP and President Joseph Mahady got $9.8 million, up from $7.2 million. Even ex-execs did well; former chairman Robert Essner made $20.9 million, down from $24.1 million last year, while Ex-SVP of R&D Robert Ruffalo Jr. made $4.7 million, down from $6.7 million in 2007.

- get the news from CNBC
- check out BNet Pharma's take
- see Salary.com's rep data

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.